← The feed Many Minded · The brief
HEALTH · forward · impact 2/5 · 2026-11-18

Same reprogramming dose, different results in skin, T cells and vessel lining

A Gladstone preprint with Shinya Yamanaka finds partial reprogramming plays out differently in three human cell types, a caution on the road to rejuvenation.

A bioRxiv preprint from Gladstone Institutes researchers, including Shinya Yamanaka, tested partial reprogramming in three human cell types: skin fibroblasts, cytotoxic T cells and aortic endothelial cells. Each type came from four donors of both sexes, aged 48 to 63. The team sorted individual cells into three states by identity-marker and reprogramming-marker levels rather than by exposure time. Gr1 is shallow, with most identity kept. Gr2 has lost much identity without nearing pluripotency. Gr3 is closest to full reprogramming.

Outcomes diverged. OSKM was withdrawn on day 7 for fibroblasts and endothelial cells and day 5 for T cells, which advanced more readily. Endothelial cells mostly did not reach Gr3. By methylation clocks, fibroblasts showed lower estimated age in each deeper state, endothelial cells showed a substantial drop already in Gr1, and T cells showed limited change until a marked decline in Gr3. Fibroblasts beyond Gr1 had lasting growth deficits. Gr3 T cells failed to recover identity and were lost after day 11, while T-cell Gr1 expanded better than controls. Endothelial cells recovered quickly from Gr1 and Gr2 and grew well with lower epigenetic age. TOX emerged as one of few shared contributors, though its gene programs differed by cell type.

For abundance, this matters because rejuvenation medicine only becomes broadly available if it can be dosed predictably. These results suggest that target cell type shapes what a given reprogramming recipe does, which is useful for setting realistic goals. It is a caution as much as progress.

Caveats are real. This is a preprint, not peer reviewed, and donors were middle-aged only, so younger cells are untested. Recipe, schedule and target cells could change outcomes; Life Biosciences has taken a three-factor OSK approach, induced continuously for eight weeks, into human trials for optic nerve disorders. The article notes animal studies have shown functional benefits, and it leaves open what should count as rejuvenation when epigenetic age and function diverge.

Source: Lifespan.io